Skip to main content

Why you should get your Covid-19 booster and flu vaccine

 The NHS is now rolling out booster doses of Covid-19 vaccines and flu jabs. 

The number of Covid-19 cases in the UK remains very high. Vaccines are protecting us and without them, we would be seeing many more people who are seriously ill. 

However, no vaccine is 100% effective. Some Covid-19 infections will still lead to a serious illness, even in people who have received two doses of vaccine. Flu will also be a threat this winter.

We know that the protection provided by Covid-19 vaccines can weaken over time – particularly in the elderly or in people with medical problems. A booster (third) dose of a vaccine improves your immunity and reduces your risk of a serious illness. 

We want as many people as possible to receive Covid-19 boosters and flu jabs before the onset of winter when pressures on the NHS increase. 

The people being targeted for boosters are those at highest risk of serious illness and death from a Covid-19 infection. This includes people aged 50 and over, and people under 50 with certain medical conditions. NHS staff, people who live and work in care homes, and people who are the main carer of someone at high-risk are also being invited for boosters. These groups are also eligible for a flu jab.

If people don’t attend for their vaccinations this will lead to more cases of Covid-19 and flu, and increased pressures on the NHS during the winter. The number of deaths will also increase. This then may require the government to bring back some Covid-19 restrictions. 

By getting a Covid-19 booster and a flu jab, you are protecting yourself and the other people you live and work with. So please go out and get your vaccinations as soon as you can. 

A version of this article was first published in the Daily Express.

Comments

Post a Comment

Popular posts from this blog

The Hidden Cost of Cheaper NHS Contracts: Losing Community Trust

NHS budgets are under considerable pressure. It is therefore unsurprising that many NHS Integrated Care Boards (ICBs) In England will aim to prioritise price in contract awards, But this approach is a significant threat to community-centred healthcare. While competitive tendering is a legally required, an excessive focus on costs in awarding NHS contracts risks overshadowing key factors such as established community trust, local expertise, and the long-term impact on continuity of care. This shift towards cheaper, often external, commercial providers threatens to cut the links between communities and their local health services. The argument that competitive tendering is solely about legal compliance, and not cost, is undermined by the very nature of such tendering, which by design encourages the lowest bid. This approach risks eroding the social fabric of local healthcare provision, where established relationships and understanding of specific community needs are essential. Establishe...
1 comment
Read more

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...
5 comments
Read more

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...
Post a Comment
Read more